Author

N. Prutsch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

M. W. Zimmerman· 3 shared A. T. Look· 2 shared S. He· 2 shared A. Berezovskaya· 1 shared A. Boersma· 1 shared A. D. Durbin· 1 shared A. Pichler· 1 shared A. T. W. Look· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. W. Zimmerman

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge, N. Prutsch, M. W. Zimmerman, T. Eder, B. Maurer, C. Wagner, S. Schoenefeldt, K. Spirk, A. Pichler, T. Pemovska, C. Schweicker, D. Poeloeske, D. Jungherz, , R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells by XPO1 inhibitors

C. Jing, N. Prutsch, S. He, M. W. Zimmerman, Y. Landesman, A. T. W. Look

This study identifies XPO1 inhibitors as selective killers of TET2-mutant HSPCs and AML cells through apoptosis, without DNA damage.

bioRxiv · Oct 12, 2022 · PreprintCancer Biology

STAT3 cooperates with the core transcriptional regulatory circuitry to drive MYC expression and oncogenesis in anaplastic large cell lymphoma

N. Prutsch, S. He, A. Berezovskaya, A. D. Durbin, N. V. Dharia, K. Stegmaier, J. D. Matthews, L. Hare, S. D. Turner, L. Kenner, O. Merkel, R. A. Young, B. J. Abraham, A. T. Look, M. W. Zimmerman

This study identifies STAT3's role in driving MYC expression and oncogenesis in ALCL by cooperating with a core transcriptional regulatory circuit.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology